Skip to main content
. 2020 May 26;11(21):1953–1960. doi: 10.18632/oncotarget.27602

Table 1. Comparison of patient clinicopathologic features based on EGFR mutation status.

EGFR mutated EGFR wildtype P-value
Number of Cases, N 142 140
 Stage 1 107 106
 Stage 2 13 13
 Stage 3 22 21
Age at diagnosis, mean (SD) 67.4 (9.7) 67.2 (9.4) 0.83
 Stage 1 67.8 (9.5) 67.3 (9.3) 0.74
 Stage 2 70.4 (6.8) 66.1 (11.1) 0.25
 Stage 3 63.9 (11.4) 67.0 (9.0) 0.33
Gender—Female, N (%) 104 (73%) 96 (69%) 0.46
 Stage 1 77 (72%) 72 (68%) 0.62
 Stage 2 9 (69%) 11 (85%) 0.64
 Stage 3 18 (82%) 13 (62%) 0.26
% with high risk histologic features* 47 (35%) 42 (37%) 0.81
 Stage 1 29 (28%) 27 (31%) 0.79
 Stage 2 8 (62%) 8 (62%) > 0.99
 Stage 3 10 (53%) 7 (54%) > 0.99
% receiving standard of care** 130 (92%) 118 (86%) 0.16
 Stage 1 102 (95%) 93 (89%) 0.12
 Stage 2 7 (54%) 6 (46%) > 0.99
 Stage 3 21 (95%) 19 (95%) > 0.99

*High risk histologic features = visceral pleural invasion, lympho-vascular invasion, poor differentiation, histologic transformation, positive margins, lepidic spread or infarction/necrosis. **Standard of care defined per NCCN guidelines based on stage of disease. Stage I disease received definitive surgical management and stage II disease received surgery or radiation followed by adjuvant chemotherapy. For stage III standard of care treatment involved multi-disciplinary treatment. Patients with resectable disease received neoadjuvant chemotherapy +/− radiation followed by surgery. For unresectable disease, patients received chemoradiation followed by immunotherapy.